INTERNATIONAL COMPARISON OF HTA DECISIONS FOR ORPHAN AND NON-ORPHAN ONCOLOGY DRUGS

被引：0
|
作者：
Achour, L. [1 ]
Hanna, E. [2 ]
Borissov, B. N. [3 ]
Ma, F. [4 ]
Toumi, M. [5 ]
机构：
[1] Paris Dauphine Univ, Paris, France
[2] Creat Ceut, Paris, France
[3] Prescriptia Ltd, Sofia, Bulgaria
[4] Creat Ceut, Beijing, Peoples R China
[5] Aix Marseille Univ, Marseille, France
来源：
VALUE IN HEALTH | 2018年 / 21卷
关键词：
D O I：
10.1016/j.jval.2018.07.174
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN105
引用
下载
收藏
页码：S23 / S23
页数：1
相关论文
共 50 条
  • [31] Comparison of the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) in clinical trials supporting US Food and Drug Administration (FDA) approval of orphan vs. non-orphan drugs
    Molto Valiente, C.
    Tibau, A.
    Ocana Fernandez, A.
    Templeton, A.
    del Carpio Huerta, L.
    Del Paggio, J.
    Barnadas, A.
    Booth, C.
    Amir, E.
    ANNALS OF ONCOLOGY, 2017, 28
  • [32] A COMPARISON OF ONCOLOGY AND NON-ONCOLOGY ORPHAN DRUG PRICES IN EUROPE
    Young, K. E.
    Soussi, I
    Toumi, M.
    VALUE IN HEALTH, 2017, 20 (05) : A31 - A31
  • [33] ORPHAN DRUGS VERSUS ULTRA-ORPHAN DRUGS: PRICE COMPARISON IN ENGLAND
    Chachoua, L.
    Hanna, E.
    Zhou, J.
    Dussart, C.
    Toumi, M.
    VALUE IN HEALTH, 2018, 21 : S107 - S107
  • [34] COMPARISON OF TIME TO REIMBURSEMENT RECOMMENDATIONS OF (ORPHAN-) ONCOLOGY DRUGS IN EUROPE
    Nientker, L.
    Trip, A. M.
    Hensen, M.
    VALUE IN HEALTH, 2019, 22 : S504 - S504
  • [35] ANALYSIS OF ORPHAN DRUGS REIMBURSEMENT IN MAJOR EUROPEAN HTA AGENCIES
    Houzelot, D.
    Heng, C.
    Perinaud, A.
    VALUE IN HEALTH, 2016, 19 (07) : A602 - A602
  • [36] UK HEALTH TECHNOLOGY ASSESSMENT OF ORPHAN DRUGS FOR RARE ONCOLOGY VERSUS RARE DISEASE: DOES ORPHAN DESIGNATION MAKE ANY DIFFERENCE IN HTA PROCESS?
    Kelly, S.
    VALUE IN HEALTH, 2018, 21 : S467 - S467
  • [37] Understanding orphan and non-orphan adolescents' sexual risks in the context of poverty: a qualitative study in Nyanza Province, Kenya
    Juma, Milka
    Alaii, Jane
    Bartholomew, L. Kay
    Askew, Ian
    Van den Born, Bart
    BMC INTERNATIONAL HEALTH AND HUMAN RIGHTS, 2013, 13
  • [38] COMPARATIVE ANALYSIS OF CLINICAL TRIAL ATTRIBUTES IN PIVOTAL STUDIES FOR ORPHAN VS. NON-ORPHAN ONCOLOGY PRODUCTS FDA-APPROVED BETWEEN 2011 AND 2015
    Ansari, W.
    Infante, K.
    VALUE IN HEALTH, 2016, 19 (07) : A750 - A750
  • [39] COMPARISON OF RECENT HTA APPRAISALS OF ORPHAN DRUGS BY NICE, SMC AND HAS IN 2015-2017
    Ziomek, J.
    Vlachaki, I
    Taveau, C.
    Delaitre, C.
    VALUE IN HEALTH, 2017, 20 (09) : A570 - A570
  • [40] No difference in between-country variability in use of newly approved orphan and non-orphan medicinal products - a pilot study
    Stolk, Pieter
    Heemstra, Harald E.
    Leufkens, Hubert G. M.
    Bloechl-Daum, Brigitte
    Heerdink, Eibert R.
    ORPHANET JOURNAL OF RARE DISEASES, 2009, 4
12345